As per clinical trials for advanced stage III or IV melanoma patients were given ipilimumab, a monoclonal antibody in contrast to CTL antigen 4 (CTL4) with DCs loaded with mRNA coding melanoma-related antigens with TriMix showed a reduction amongst recurring tumors [157]. The gene discussed is SLC44A4; the disease is melanoma.